Q1 2013 Results (Array Biopharma) - Oct 30, 2012 - Anticipated data from P1 trial for myelodysplastic syndrome at ASH 2012 / H1 2013; Anticipated FDA meeting by Dec 2013; Anticipated initiation of registration trial for myelodysplastic syndrome by Dec 2013; Anticipated reporting of dose escalation trial with improved formulation in myelodysplastic syndrome by Dec 2013; Anticipated decision of P3 / pivotal trial for cancer in 2013
Anticipated FDA event • Anticipated new P3 trial • Anticipated new trial • Anticipated P1 data • Oncology
|